https://seekingalpha.com/news/4068940-scisparc-shares-up-on-patents-filed-for-psychedelic-compounds-with-clearmind?source=feed_tag_israel
Feb 20, 2024 - SciSparc shares surge 45% as Clearmind Medicine files three patent applications for psychedelic drug combinations.
0
sa:5651967984715261889
0
https://www.zacks.com/stock/news/2228515/etsy-gears-up-to-report-q4-earnings-what-s-in-the-cards?cid=CS-ZC-FT-analyst_blog|earnings_preview-2228515
Feb 20, 2024 - ETSY's fourth-quarter 2023 earnings are likely to have gained from growing momentum among active buyers and active sellers.
zc:3729828222099134853
0
https://www.denverpost.com/2024/02/19/colorado-lawmakers-youth-social-media-apps-instagram-tiktok-facebook/
Feb 19, 2024 - Two bills at the Colorado Capitol would regulate tech giants by requiring more attention on young people's use of social media. One would require app makers to deliver pop-up warnings late at night that urge heavy users younger than 18 to close the app.
0
dp:5080838864915145309
0
https://www.denverpost.com/2024/02/19/wait-what-things-are-looking-up-for-home-buyers/
Feb 19, 2024 - Here are some reasons that 2024 might be better for home buyers than the previous two years.
0
dp:-697648873543913460
0
https://seekingalpha.com/article/4671425-fx-risk-proxies-setting-up-for-rally-against-usd-technical-analysis?source=feed_tag_forex
Feb 19, 2024 - FX risk proxies could mirror the strength seen in the Russell 2000, which broke out higher from a 2-year base. Explore more details here.
0
sa:-1532285628075247563
0
https://www.zacks.com/stock/news/2228091/cellebrite-di-ltd-clbt-is-up-20-78-in-one-week-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_10-2228091
Feb 19, 2024 - Does Cellebrite DI Ltd. (CLBT) have what it takes to be a top stock pick for momentum investors? Let's find out.
zc:187780436564994289
0
https://www.zacks.com/stock/news/2228028/moderna-mrna-gears-up-for-q4-earnings-will-it-top-estimates?cid=CS-ZC-FT-analyst_blog|earnings_preview-2228028
Feb 19, 2024 - Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports fourth-quarter earnings.
zc:-8195830911249071635
0
https://www.zacks.com/stock/news/2228024/live-nation-lyv-gears-up-for-q4-earnings-what-s-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2228024
Feb 19, 2024 - Live Nation's (LYV) fourth-quarter 2023 results are likely to reflect the impacts of an increase in demand for live events, a rise in average per-fan spending and a hike in ticket pricing.
zc:2423833125505291539
0
https://www.zacks.com/stock/news/2227848/gear-up-for-mister-car-wash-mcw-q4-earnings-wall-street-estimates-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2227848
Feb 19, 2024 - Beyond analysts' top -and-bottom-line estimates for Mister Car Wash (MCW), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
zc:-4876406989956519749
0
https://www.zacks.com/stock/news/2227883/gear-up-for-on24-ontf-q4-earnings-wall-street-estimates-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2227883
Feb 19, 2024 - Evaluate the expected performance of ON24 (ONTF) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
zc:-1559713167416183988
0